Fuji Pharma Co

Fuji Pharma Co PEG

The PEG Ratio (Price/Earnings-to-Growth) of Fuji Pharma Co (4554.T) as of Oct 18, 2026 is 5.12. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 2.50 — a change of 104.90% (higher).

PEG

5.12

YoY

104.90%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Fuji Pharma Co is 2025 5.12 . PEG Ratio (Price/Earnings-to-Growth) of Fuji Pharma Co was 2024 2.50 . It decreases by 104.90% higher compared to the previous year.

The Fuji Pharma Co PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2018
4.56 JPY
Jan 1, 2019
5.19 JPY
Jan 1, 2020
7.37 JPY
Jan 1, 2021
6.32 JPY
Jan 1, 2022
5.70 JPY
Jan 1, 2023
4.48 JPY
Jan 1, 2024
2.50 JPY
Jan 1, 2025
5.12 JPY
The Fuji Pharma Co PEG history
YEARPEGYoY
5.12+104.90%
2.50-44.12%
4.48-21.48%
5.70-9.83%
6.32-14.27%
7.37+42.06%
5.19+13.84%
4.56-2.11%
4.66-35.84%
7.26-1.23%
7.35-0.67%
7.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fuji Pharma Co Stock analysis

What does Fuji Pharma Co do? Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fuji Pharma Co stock

PEG Ratio (Price/Earnings-to-Growth) of Fuji Pharma Co is 5.12 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Fuji Pharma Co changed from 2.50 to 5.12, representing a 104.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Fuji Pharma Co since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Fuji Pharma Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Fuji Pharma Co

All Key Metrics — Fuji Pharma Co